Mr. Speaker, one year ago Canada's negotiator on CETA told the trade committee that government had done internal analysis on the issue of drug costs. However, the minister refused us that study stating: “No, they're not available to this committee”.
Now the Canadian Press, based on these studies, has confirmed our worst fear that European patents will increase Canadian drug costs by $2 billion per year.
Will the minister admit to these additional drug costs to Canadians as a result of CETA, and will he now allow the committee access to that analysis in full?